SpringWorks Therapeutics Inc (SWTX)
36.45
-0.10
(-0.27%)
USD |
NASDAQ |
Nov 15, 16:00
36.43
-0.02
(-0.05%)
After-Hours: 20:00
SpringWorks Therapeutics Research and Development Expense (TTM): 179.09M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 179.09M |
| March 31, 2024 | 170.58M |
| December 31, 2023 | 150.49M |
| September 30, 2023 | 144.76M |
| June 30, 2023 | 143.38M |
| March 31, 2023 | 145.54M |
| December 31, 2022 | 146.12M |
| September 30, 2022 | 137.54M |
| June 30, 2022 | 124.34M |
| March 31, 2022 | 118.40M |
| December 31, 2021 | 101.68M |
| Date | Value |
|---|---|
| September 30, 2021 | 87.59M |
| June 30, 2021 | 78.65M |
| March 31, 2021 | 59.51M |
| December 31, 2020 | 51.86M |
| September 30, 2020 | 48.77M |
| June 30, 2020 | 45.59M |
| March 31, 2020 | 43.85M |
| December 31, 2019 | 42.54M |
| September 30, 2019 | 34.08M |
| June 30, 2019 | 26.74M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
42.54M
Minimum
Dec 2019
179.09M
Maximum
Jun 2024
106.33M
Average
118.40M
Median
Mar 2022
Research and Development Expense (TTM) Benchmarks
| Ocugen Inc | 33.34M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.61M |